Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
暂无分享,去创建一个
R. Rizzoli | J. Gallagher | J. Adachi | S. Adami | H. Resch | Andrea T Wang | D. Kendler | R. Feldman | R. Wagman | S. Palacios | C. Zapalowski | A. Wang | L. Kalouche-Khalil | R. Rizzoli | A. Wang | Heinrich Resc
[1] L. Lix,et al. The Importance of Previous Fracture Site on Osteoporosis Diagnosis and Incident Fractures in Women , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Pim A de Jong,et al. Prevalent Vertebral Fractures on Chest CT: Higher Risk for Future Hip Fracture , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] C. Cooper,et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.
[4] C. Benhamou,et al. Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial , 2013, Obstetrics and Gynecology.
[5] R. Langer,et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health , 2013, Climacteric : the journal of the International Menopause Society.
[6] C. Cooper,et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle , 2013, Osteoporosis International.
[7] B. Mcgowan,et al. Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008 , 2013, Irish Journal of Medical Science.
[8] S. Sen,et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study , 2013, BMC Women's Health.
[9] S. Silverman,et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] J. Kanis,et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] J. van der Palen,et al. The (a)-Symptomatic Vertebral Fracture , 2012, Geriatric orthopaedic surgery & rehabilitation.
[12] C. Christiansen,et al. Individualizing osteoporosis therapy , 2012, Osteoporosis International.
[13] S. Cummings,et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] C. Cooper,et al. Osteoporosis: burden, health care provision and opportunities in the EU , 2011, Archives of osteoporosis.
[15] S. Cummings,et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. , 2011, The Journal of clinical endocrinology and metabolism.
[16] Paul E. Johnson,et al. Predictors of Patients’ Perceived Need for Medication to Prevent Fracture , 2011, Medical care.
[17] A. LaCroix,et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. , 2010, Mayo Clinic proceedings.
[18] B. Wolffenbuttel,et al. Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations , 2010, Osteoporosis International.
[19] W. Leslie,et al. Time since prior fracture is a risk modifier for 10‐year osteoporotic fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] Sei J. Lee,et al. Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture , 2010, Journal of the American Geriatrics Society.
[21] Jacques P. Brown,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[23] S. Silverman,et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. , 2009, The American journal of medicine.
[24] H. Teede,et al. Fracture prevention strategies in patients presenting to Australian hospitals with minimal‐trauma fractures: a major treatment gap , 2007, Internal medicine journal (Print).
[25] B. Edwards,et al. Prior Fractures are Common in Patients with Subsequent Hip Fractures , 2007, Clinical orthopaedics and related research.
[26] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[27] Krista F Huybrechts,et al. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.
[28] L. Giangregorio,et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. , 2006, Seminars in arthritis and rheumatism.
[29] W. Shen,et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures , 2005, Osteoporosis International.
[30] J. Reginster,et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.
[31] O Johnell,et al. A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.
[32] Jacques P. Brown,et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis , 2004, Current medical research and opinion.
[33] T. Spector,et al. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.
[34] R. Cumming,et al. Osteoporotic fracture: missed opportunity for intervention , 2003, Osteoporosis International.
[35] C. Cooper,et al. Epidemiology of fractures in England and Wales. , 2001, Bone.
[36] C. Cooper,et al. Epidemiology of osteoporosis. , 2001, Rheumatic diseases clinics of North America.
[37] T. Abbott,et al. Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[38] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[39] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[40] C. Cooper,et al. Epidemiology of osteoporosis. , 2002, Best practice & research. Clinical rheumatology.
[41] M. Nevitt,et al. Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] Jacques P. Brown,et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. , 2014, Bone.
[43] J. Palen,et al. The (a)-Symptomatic Vertebral Fracture: A Frequently Discovered Entity With Clinical Relevance in Fracture Patients Screened on Osteoporosis , 2012 .
[44] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.